CY1112740T1 - ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12) - Google Patents

ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12)

Info

Publication number
CY1112740T1
CY1112740T1 CY20121100427T CY121100427T CY1112740T1 CY 1112740 T1 CY1112740 T1 CY 1112740T1 CY 20121100427 T CY20121100427 T CY 20121100427T CY 121100427 T CY121100427 T CY 121100427T CY 1112740 T1 CY1112740 T1 CY 1112740T1
Authority
CY
Cyprus
Prior art keywords
dcs
interleykin
expressing
treatment
specific
Prior art date
Application number
CY20121100427T
Other languages
English (en)
Inventor
Thomas Felzmann
Original Assignee
Forschungsinstitut Für Krebskranke Kinder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungsinstitut Für Krebskranke Kinder filed Critical Forschungsinstitut Für Krebskranke Kinder
Publication of CY1112740T1 publication Critical patent/CY1112740T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει την χρήση ενεργών δενδριτικών κυττάρων (DCs) που αποδεσμεύουν ιντερλευκίνη 12 (IL-12) τα οποία φορτώνονται με ένα αντιγόνο έναντι ειδικού παθογόνου ή ειδικού όγκου και, λόγω της κατεργασίας με λιποπολυσακχαρίδιο (LPS) και ιντερφερόνη-γάμμα (IFN-y), αποδεσμεύουν IL-12, για την παρασκευή φαρμάκου για την αγωγή ασθενούς έχοντας λοίμωξη με το εν λόγω ειδικό παθογόνο ή για την αγωγή ασθενούς έχοντας τον εν λόγω ειδικό όγκο.
CY20121100427T 2002-09-13 2012-05-08 ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12) CY1112740T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0137502A AT412145B (de) 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
EP03794972A EP1537203B1 (en) 2002-09-13 2003-08-29 USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12)

Publications (1)

Publication Number Publication Date
CY1112740T1 true CY1112740T1 (el) 2016-02-10

Family

ID=31892564

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100427T CY1112740T1 (el) 2002-09-13 2012-05-08 ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12)

Country Status (12)

Country Link
US (1) US7867488B2 (el)
EP (1) EP1537203B1 (el)
JP (1) JP2005538167A (el)
AT (2) AT412145B (el)
AU (1) AU2003260473B2 (el)
CA (1) CA2494216C (el)
CY (1) CY1112740T1 (el)
DK (1) DK1537203T3 (el)
ES (1) ES2381870T3 (el)
PT (1) PT1537203E (el)
SI (1) SI1537203T1 (el)
WO (1) WO2004024900A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004023238D1 (de) * 2004-05-11 2009-10-29 Shukokai Inc Methoden zur Kultivierung von Antigen presentierenden Immunzellen
AU2013206016B2 (en) * 2005-12-08 2016-08-11 Northwest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
CN103589684A (zh) * 2005-12-08 2014-02-19 西北生物治疗药物公司 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
EP3033417B1 (en) * 2012-06-27 2019-12-25 Kenichiro Hasumi Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
WO2014149871A1 (en) * 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
FR2796961B1 (fr) * 1999-07-29 2003-05-02 Chu Montpellier Procede d'obtention de cellules dentritiques, les cellules dentritiques ainsi obtenues et leurs utilisations a des fins cliniques
WO2001039600A1 (en) * 1999-12-03 2001-06-07 University Of Massachusetts Use of hsp27 as an anti-inflammatory agent
AU2000227285A1 (en) * 2000-01-14 2001-07-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
US20030003579A1 (en) * 2000-10-24 2003-01-02 Norimitsu Kadowaki Dendritic cells; methods
KR101803702B1 (ko) * 2001-09-06 2017-12-01 노쓰웨스트 바이오써라퓨틱스, 인크. Ｔｈ-1 반응을 위한 단구성 수지상 세포 및 Ｔ 세포를 프라이밍하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
PT1537203E (pt) 2012-05-21
CA2494216A1 (en) 2004-03-25
ATE544847T1 (de) 2012-02-15
EP1537203A1 (en) 2005-06-08
AU2003260473A1 (en) 2004-04-30
ES2381870T3 (es) 2012-06-01
EP1537203B1 (en) 2012-02-08
ATA13752002A (de) 2004-03-15
SI1537203T1 (sl) 2012-06-29
US20060177420A1 (en) 2006-08-10
US7867488B2 (en) 2011-01-11
CA2494216C (en) 2013-07-09
AU2003260473B2 (en) 2008-08-07
AT412145B (de) 2004-10-25
WO2004024900A1 (en) 2004-03-25
JP2005538167A (ja) 2005-12-15
DK1537203T3 (da) 2012-05-14

Similar Documents

Publication Publication Date Title
CY1112740T1 (el) ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12)
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1112962T1 (el) 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων
ES2361993T5 (es) Tratamiento con enzimas de productos alimenticios para celiaquía
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
CY1120720T1 (el) Υπομοναδα απομονωσης και σχετικες συνθεσεις και μεθοδοι
CY1107103T1 (el) Νεα παραγωγα νουκλεοζιτων με τροποποιημενη με καρβοξαμιδινη μονοκυκλικη βαση
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
CY1109981T1 (el) Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
CY1118936T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για την αγωγη ή την προληψη νοσου σχετιζομενης με οξαλικο
CY1109454T1 (el) Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
CY1112879T1 (el) Συνθεση εμβολιου
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
ATE344029T1 (de) Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern
CY1107440T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CY1109141T1 (el) Χιμαιρικα σωματιδια παρομοια με αρτηριοϊους
CY1109059T1 (el) Μεθοδοι επαγωγης μιας κυτταροτοξiκης ανοσολογικης αποκρισης και συνθεσεις ανασυνδυασμενου πιθηκειου αδενοϊου χρησιμες για αυτες